ADMA Biologics (ADMA) Stock Price & Analysis

ADMA$13.68+0.44 +3.32%
BiotechnologyValue StockHigh Quality
Compare
Market cap$3.03BEnterprise value$2.56BRevenue (TTM)$512.27MMarket position—

Score

68
Bullish
Value
68
Quality
88
Growth
47

AI Analysis

Snapshot

ADMA Biologics looks like a quality compounder first — Quality 88/100 and an overall 68/100. Under the hood: P/E 15.4, plus revenue compounding ~51% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

68
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

47
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

88
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

ADMA Biologics, Inc. (ADMA) last printed $13.68. Equity value is $3.03B. Trailing earnings multiple 18.48. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$10.66M$22.76M$16.99M$29.35M$42.22M$80.94M$154.08M$258.21M$426.45M$510.17M

About

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

ADMA Biologics (ADMA) Stock Price & Analysis

ADMA price $13.68 +0.44 +3.32%

Ticker
ADMA
Price
$13.68
Change
+0.44 +3.32%
Market cap
$3.03B
P/E
18.48
Forward P/E
13.86
Dividend yield
0.00%
Beta
0.77
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
68
Quality
88
Growth
47

Stocklytics score rationale: value 68, quality 88, growth 47.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener